Comorbid Conditions in the Patient with Advanced Prostate Cancer Podcast (2023)
Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessment, the AUA has produced a series of podcasts to update urologists on the latest advancements in androgen deprivation therapy (ADT) and prostate cancer treatment. This activity will focus on the following topic:
Comorbid Conditions in the Patient with Advanced Prostate Cancer
ACKNOWLEDGEMENTS:
This series is supported by independent educational grants from:
Myovant Sciences LTD
Pfizer, Inc.
Target Audience
- Urologists
- Advanced Practice Providers (APPs)
Learning Objectives
At the conclusion of these activities, participants will be able to:
- Oversee comorbidities and describe their management in the context of advanced prostate cancer treatment.
- Assess the potential cardiovascular risk associated with ADT.
- Differentiate the roles of the urologist, other specialists and advanced practice providers and identify opportunities for shared care and team-based approaches of patients with prostate cancer.
EDUCATION COUNCIL DISCLOSURES
Education Council Disclosures_2022.pdf
COI REVIEW WORK GROUP DISCLOSURES
COI Review Work Group Disclosures_2023.pdf
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
Jay Raman, MD
Rana Mckay, MD
Kristen Scarpato, MD
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by listening to the podcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.
Estimated time to complete this activity: 0.50 hours
Release Date: February, 2023
Expiration Date: February, 2024
ACCREDITATION:
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION:
The American Urological Association designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
OTHER LEARNERS:
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group for identification of conflicts of interest. The AUA COI Review Work Group, working with the program directors and/or editors, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or AUA COI Review Work Group.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Available Credit
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Non-Physician Participation